Form 4: Olema Pharmaceuticals Executive Granted Stock Options

Shawnte Mitchell, Chief Legal Officer of Olema Pharmaceuticals, was granted stock options to purchase 450,000 shares of common stock.

Summary

• On February 28, 2025, Shawnte Mitchell, the Chief Legal Officer of Olema Pharmaceuticals, Inc., was granted stock options.
• These options allow Mitchell to purchase 450,000 shares of Olema Pharmaceuticals' common stock at an exercise price of $4.37 per share.
• The options vest over time, with 25% vesting on February 28, 2026, and the remaining options vesting monthly thereafter, contingent upon continuous service.
• The options expire on February 27, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is moderately positive as it indicates ongoing investment in key personnel.

Positives

• The granting of stock options to the Chief Legal Officer aligns their interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Granting stock options is a common practice in the pharmaceutical industry to incentivize executives and align their interests with the company's long-term success. This aligns with standard compensation practices to attract and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, often used by companies like Amgen, Pfizer, and Johnson & Johnson.
• The vesting schedule of 25% after one year followed by monthly vesting is a fairly standard approach to incentivize long-term commitment, similar to practices seen at other biotech firms.
• The exercise price of $4.37 would need to be compared to the market price of OLMA stock at the time of the grant to assess its competitiveness and potential value to the executive.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the company is investing in its leadership.
• Employees may see this as a positive sign of stability and growth within the company.

Key Dates